Alvogen nabs four Pfizer products; Brazil's pharma market to approach $48B by 2020: report;

> Alvogen has acquired a portfolio of four pharma products from Pfizer ($PFE). Release

> Brazil's pharma market will near $48 billion by 2020, GlobalData says. Release

> Amneal has created a new biosciences unit that will focus on injectables, oncologics, biosimilars and other products that have high barriers to entry. Release

> Mylan ($MYL) has launched a generic of Pfizer's anti-infective combo Zosyn. Release

> British health secretary Jeremy Hunt is to create tough new rules designed to criminalize some gifts and financial payments between doctors and pharma companies. Report

Suggested Articles

After showing Nucala could cut the rates of flares for hypereosinophilic syndrome, GSK is planning regulatory filings in 2020.

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.